Diabetes

Amino acid-based therapy for glucose homeostasis and TIIDM: Valine, a non-essential amino acid,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 11/March/2018, 10.13 pm
Amino acid-based therapy for glucose homeostasis and TIIDM: Valine, a non-essential amino acid,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 11/March/2018, 10.13 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that…

read more

Combination (Amino acid + Polyamine) therapy for reversing TIIDM: A pharmaceutical mixture encompassing  L-Arginine and Spermidine augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM, via up regulation of its target gene, 8/March/2018, 6.55 am
Combination (Amino acid + Polyamine) therapy for reversing TIIDM: A pharmaceutical mixture encompassing  L-Arginine and Spermidine augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM, via up regulation of its target gene, 8/March/2018, 6.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Amino acid-based therapy for body weight control, energy homeostasis and TIIDM: L-Arginine, a non-essential amino acid that aids in blood flow and in maintaining optimal nitric oxide levels, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/March/2018, 6.36 am
Amino acid-based therapy for body weight control, energy homeostasis and TIIDM: L-Arginine, a non-essential amino acid that aids in blood flow and in maintaining optimal nitric oxide levels, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/March/2018, 6.36 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Amino acid-based therapy for diabetes (TIDM): L-Arginine increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 5/March/2018, 3.09 pm
Amino acid-based therapy for diabetes (TIDM): L-Arginine increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 5/March/2018, 3.09 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Amino acid-based therapy for diabetes (TIDM): Glycine, a non-essential amino acid and inhibitory neurotransmitter, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 4/March/2018, 12.23 pm
Amino acid-based therapy for diabetes (TIDM): Glycine, a non-essential amino acid and inhibitory neurotransmitter, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 4/March/2018, 12.23 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Amino acid-based therapy for TIIDM and obesity-associated metabolic deficits: Glycine, a non-essential amino acid and inhibitory neurotransmitter,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/March/2018, 11.45 am
Amino acid-based therapy for TIIDM and obesity-associated metabolic deficits: Glycine, a non-essential amino acid and inhibitory neurotransmitter,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/March/2018, 11.45 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more
Start Typing